PROMETRIUM (progesterone) by Fresenius Kabi is clinical pharmacology prometrium capsules are an oral dosage form of micronized progesterone which is chemically identical to progesterone of ovarian origin. First approved in 1998.
Drug data last refreshed 2d ago
PROMETRIUM is an oral micronized progesterone capsule that is chemically identical to naturally occurring ovarian progesterone. It is indicated for hormone replacement therapy, contraception, and treatment of conditions including infertility, endometrial hyperplasia, preterm birth prevention, and multiple other gynecological and neurological conditions. The drug works by binding to progesterone receptors to modulate hormonal signaling and reproductive/metabolic processes.
As a product approaching loss of exclusivity with minimal Part D spending, the brand team is likely focused on cost management and efficiency rather than significant commercial expansion.
CLINICAL PHARMACOLOGY PROMETRIUM Capsules are an oral dosage form of micronized progesterone which is chemically identical to progesterone of ovarian origin. The oral bioavailability of progesterone is increased through micronization. Pharmacokinetics A. Absorption After oral administration of…
Worked on PROMETRIUM at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert
Exogenous Progesterone as Ovulation Trigger
Comparison of Two Vaginal Progesterone Forms in Frozen Embryo Transfer
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPROMETRIUM roles are unlikely to be high-growth positions given the product's approaching LOE status and minimal Part D spending footprint. Career opportunities are concentrated in generic transition management, healthcare economics, and supply chain optimization rather than brand building or commercial expansion.